Bluebird Bio, based in Cambridge, MA, is a pioneering company focused on developing curative gene therapies for patients and their families. With a decade of experience in gene therapy, they are setting the standard in the field and have the largest ex vivo gene therapy data set in the world.
Their one-time gene therapy treatments, designed to deliver functional copies of genes to patients' cells, aim to provide more "bluebird days" for those affected by diseases such as beta thalassemia, cerebral adrenoleukodystrophy, and sickle cell disease. Bluebird Bio is dedicated to advancing the field of gene therapy through collaboration, diversity, equity, and inclusion, ensuring that patient advocacy and well-being remain at the forefront of their mission.
Generated from the website